blog.aids.gov — HIV Policy & Programs. Research. New Media.
HIV Policy & Programs. Research. New Media.
Over the past year and a half, many of you followed the AIDS.gov blog post series Future Directions for NIAID HIV Research by Dr. Carl Dieffenbach, Director of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH. Last week, NIAID advanced those efforts by issuing several requests for applications (RFAs)…
This week, over 5,000 delegates from around the world are attending the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome, Italy. This biannual conference is the world’s largest open scientific conference on HIV/AIDS, and provides “a unique opportunity for the world’s leading scientists, clinicians, public health experts and…
Co-authored by Margaret (Peggy) Johnston, Ph.D., Senior Scientific Consultant, NIAID.
HIV Vaccine Awareness Day provides an opportunity to acknowledge the more than 35,000 individuals who have volunteered for preventive HIV vaccine trials over the past 25 years. Without their participation, the modest success that we have achieved…
On Saturday, February 26th, I attended a day-long meeting organized by the Centers for Disease Control and Prevention (CDC) and hosted by the Fenway Community Health Center in Boston. The theme of the meeting was “Moving forward with PrEP Implementation.” Meeting participants included researchers involved in the original iPrEX study and other ongoing HIV prevention…
WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research. The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…
Scientists have discovered two potent human antibodies that can stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory. The scientists also have demonstrated how one of these disease-fighting proteins accomplishes this feat. According to the scientists, these antibodies could be used to design improved HIV vaccines, or…
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, shared the latest scientific information with the conference delegates about the actual steps that the human immunodeficiency virus (HIV) takes when it makes contact with the human genital tract (through exposure to semen or vaginal secretions) which result in infection.Understanding, in detail,…
In late September, the U.S. federal government announced news on HIV vaccine research that sparked interest around the world. A trial called RV144, or the Thai HIV vaccine clinical trial , showed that the experimental vaccine regimen was safe and about 31 percent effective in preventing HIV infection. Although the vaccine regimen had a very…
